RT Journal Article
SR Electronic
T1 Diagnostic accuracy of Loop mediated isothermal amplification coupled to Nanopore sequencing (LamPORE) for the detection of SARS-CoV-2 infection at scale in symptomatic and asymptomatic populations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.15.20247031
DO 10.1101/2020.12.15.20247031
A1 Ptasinska, Anetta
A1 Whalley, Celina
A1 Bosworth, Andrew
A1 Poxon, Charlotte
A1 Bryer, Claire
A1 Machin, Nicholas
A1 Grippon, Seden
A1 Wise, Emma L
A1 Armson, Bryony
A1 Howson, Emma L A
A1 Goring, Alice
A1 Snell, Gemma
A1 Forster, Jade
A1 Mattocks, Chris
A1 Frampton, Sarah
A1 Anderson, Rebecca
A1 Cleary, David
A1 Parker, Joe
A1 Boukas, Konstantinos
A1 Graham, Nichola
A1 Cellura, Doriana
A1 Garratt, Emma
A1 Skilton, Rachel
A1 Sheldon, Hana
A1 Collins, Alla
A1 Ahmad, Nusreen
A1 Friar, Simon
A1 Williams, Tim
A1 Godfrey, Keith M
A1 Deans, Zandra
A1 Douglas, Angela
A1 Hill, Sue
A1 Kidd, Michael
A1 Porter, Deborah
A1 Kidd, Stephen P
A1 Cortes, Nicholas J
A1 Fowler, Veronica
A1 Williams, Tony
A1 Richter, Alex
A1 Beggs, Andrew D
YR 2020
UL http://medrxiv.org/content/early/2020/12/16/2020.12.15.20247031.abstract
AB Introduction Rapid, high throughput diagnostics are a valuable tool, allowing the detection of SARS-CoV-2 in populations, in order to identify and isolate people with asymptomatic and symptomatic infections. Reagent shortages and restricted access to high throughput testing solutions have limited the effectiveness of conventional assays such as reverse transcriptase quantitative PCR (RT-qPCR), particularly throughout the first months of the COVID-19 pandemic. We investigated the use of LamPORE, where loop mediated isothermal amplification (LAMP) is coupled to nanopore sequencing technology, for the detection of SARS-CoV-2 in symptomatic and asymptomatic populations.Methods In an asymptomatic prospective cohort, for three weeks in September 2020 health care workers across four sites (Birmingham, Southampton, Basingstoke and Manchester) self-swabbed with nasopharyngeal swabs weekly and supplied a saliva specimen daily. These samples were tested for SARS-CoV-2 RNA using the Oxford Nanopore LamPORE system and a reference RT-qPCR assay on extracted sample RNA. A second retrospective cohort of 848 patients with influenza like illness from March 2020 – June 2020, were similarly tested from nasopharyngeal swabs.Results In the asymptomatic cohort a total of 1200 participants supplied 23,427 samples (3,966 swab, 19,461 saliva) over a three-week period. The incidence of SARS-CoV-2 detection using LamPORE was 0.95%. Diagnostic sensitivity and specificity of LamPORE was >99.5% in both swab and saliva asymptomatic samples when compared to the reference RT-qPCR test. In the retrospective symptomatic cohort, the incidence was 13.4% and the sensitivity and specificity were 100%.Conclusions LamPORE is a highly accurate methodology for the detection of SARS-CoV-2 in both symptomatic and asymptomatic population settings and can be used as an alternative to RT-qPCR.Competing Interest StatementCompeting interests: ADB has received travel funding to the Oxford Nanopore Community Meeting 2019 from Oxford Nanopore. The rest of the authors declare no conflict of interest.Funding StatementThe research in this study was funded by an unrestricted grant by the United Kingdom Department of Health and Social Care. ADB is currently supported by a Cancer Research UK Advanced Clinician Scientist award (C31641/A23923) and his laboratory is supported by CRUK Centre Birmingham (C17422/A25154) and the Birmingham Experimental Cancer Medicine Centre (C11497/A25127).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Research Ethics Service Committee West Midlands - South Birmingham 2002/201 Amendment Number 4All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on reasonable request and after central review